Précisez une action ou une cryptomonnaie dans la barre de recherche pour obtenir un récapitulatif
Astellas Pharma Inc
YPHAstellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex's GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. The company was founded in 1923 and is headquartered in Tokyo, Japan. Address: 2-5-1, Nihonbashi-Honcho, Tokyo, Japan, 103-8411
Analytics
Objectif de Cours de WallStreet
–Ratio C/B
128.625Rendement du dividende
4.41 %Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Chiffres clés YPH
Analyse des dividendes YPH
Croissance des dividendes sur 5 ans
76 %Croissance continue
10 annéesRatio de distribution Moyenne sur 5 ans
66 %Historique des dividendes YPH
Valorisation des titres YPH
financières YPH
Résultats | 2019 | Dynamique |